...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gene Therapy and Molecular Biology >Decreased risk of bladder cancer in men treatedwith quinazoline-based !1-adrenoceptor antagonists
【24h】

Decreased risk of bladder cancer in men treatedwith quinazoline-based !1-adrenoceptor antagonists

机译：用喹唑啉类！1-肾上腺素受体拮抗剂治疗的男性患膀胱癌的风险降低

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Previous studies documented that human bladder cancer cells are sensitive to the apoptotic effects of quinazoline- derived !1-adrenoreceptor antagonists and bladder tumors exhibit reduced tissue vascularity in response to terazosin. More recent evidence suggests that exposure to quinazoline !1-adrenorecptor antagonists leads to a significant reduction in prostate cancer incidence. This retrospective observational cohort study was conducted to determine whether male patients treated with quinazoline !1-adrenoceptor antagonists for either benign prostate hyperplasia (BPH) or hypertension have a decreased risk of developing bladder cancer. Review of the medical records of all male patients enrolled at the Lexington Veterans Administration (VA) Medical Center identified men exposed to quinazoline-based !1-adrenoceptor antagonists (Jan 1, 1998-Dec 31, 2002) for either hypertension and/or benign prostate obstructive symptoms. The whole group of 27,138 male patients was linked to the Markey Cancer Center’s Kentucky Cancer Registry (KCR), part of the NCI’s Surveillance, Epidemiology, and End Results (SEER) Program, to identify all incident bladder cancer cases diagnosed in this population. Measures of disease incidence, relative risk, and attributable risk were calculated to compare the risk of developing bladder cancer for !1-blocker-exposed versus unexposed men. A two-by-two contingency table of !1-antagonist exposure versus bladder cancer diagnoses was constructed and the relative risk was calculated. Our analysis revealed a cumulative bladder cancer incidence of 0.24% among the !1-blocker-exposed men compared to 0.42% in the unexposed group. Thus, there was a risk difference of -0.0018, which indicates that 1.8 fewer bladder cancer cases developed per 1000 exposed men. Alternatively stated, 556 men would need to be treated with quinazoline !1-blockers to prevent one case of bladder cancer. Exposure to quinazoline !1-blockers thus may have prevented 7 to 8 bladder cancer cases among the 4173 treated men during the study period .The data yield an unadjusted risk ratio of 0.57 (95% CI: 0.30, 1.08) and therefore, men treated with !1-adrenoreceptor antagonists have a 43% lower relative risk of developing bladder cancer than unexposed men (p=0.083). Our inability to determine person-years at risk of developing bladder cancer for each unexposed control patient, was a limitation for calculating an incidence ratio and rate difference. These results offer an initial indication that exposure to doxazosin and terazosin decreases the incidence of bladder cancer. This is the first epidemiological evidence that the anti-tumor action of quinazoline-based !1-antagonists may potentially translate into a protective effect from bladder cancer development.
机译：先前的研究表明，人的膀胱癌细胞对喹唑啉衍生的！1-肾上腺素受体拮抗剂的凋亡作用敏感，并且膀胱肿瘤对特拉唑嗪的反应显示组织血管减少。最近的证据表明，暴露于喹唑啉！1-肾上腺皮质激素拮抗剂可导致前列腺癌发生率显着降低。这项回顾性观察队列研究旨在确定接受喹唑啉！1-肾上腺素能受体拮抗剂治疗前列腺增生（BPH）或高血压的男性患者是否降低了患膀胱癌的风险。列克星敦退伍军人管理局（VA）医疗中心对所有男性患者的病历进行的审查发现，男性因高血压和/或良性而暴露于喹唑啉类！1-肾上腺素受体拮抗剂（1998年1月1日至2002年12月31日）前列腺阻塞症状。整个27138名男性患者与美国国家癌症研究所（NCI）的监视，流行病学和最终结果（SEER）计划的一部分，马可癌症中心的肯塔基州癌症登记处（KCR）联系在一起，以确定该人群中所有确诊的膀胱癌病例。计算疾病发病率，相对风险和可归因风险的度量，以比较暴露于！1受体阻滞剂的男性和未暴露于男性的人患膀胱癌的风险。建立了！1-拮抗剂暴露与膀胱癌诊断的2比2权变表，并计算了相对危险度。我们的分析显示，暴露于！1阻滞剂的男性中，膀胱癌的累积发病率为0.24％，而未暴露的人群中为0.42％。因此，风险差异为-0.0018，这表明每1000个暴露的男性中，膀胱癌病例减少1.8个。换句话说，为了预防一例膀胱癌，需要对556名男性进行喹唑啉！1-受体阻滞剂治疗。因此，在研究期间，暴露于喹唑啉！1-受体阻滞剂可能预防了4173例经治疗的男性中的7至8例膀胱癌病例。数据得出的未经调整的风险比为0.57（95％CI：0.30，1.08），因此接受治疗的男性与未暴露的男性相比，使用α1-肾上腺素能受体拮抗剂的人患膀胱癌的相对风险要低43％（p = 0.083）。我们无法确定每位未暴露的对照患者罹患膀胱癌的风险的人年数，这是计算发病率和比率差异的限制。这些结果初步表明，多沙唑嗪和特拉唑嗪的暴露会降低膀胱癌的发病率。这是第一个流行病学证据，表明基于喹唑啉的！1-拮抗剂的抗肿瘤作用可能会转化为膀胱癌发展的保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号